コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 as reported in patients with high-turnover, postmenopausal osteoporosis.
2 olume and osteoid and osteoblast surfaces in postmenopausal osteoporosis.
3 arkers in an ovariectomized rodent model for postmenopausal osteoporosis.
4 contribute to bone loss in diseases such as postmenopausal osteoporosis.
5 approved for the prevention and treatment of postmenopausal osteoporosis.
6 ntary therapeutic efficacy of PTHrP(1-36) in postmenopausal osteoporosis.
7 characterized by increased bone loss such as postmenopausal osteoporosis.
8 have potential as a therapeutic strategy for postmenopausal osteoporosis.
9 ramatic increases in bone mass in women with postmenopausal osteoporosis.
10 vely repress bone loss in an animal model of postmenopausal osteoporosis.
11 ed rats, an established preclinical model of postmenopausal osteoporosis.
12 relevant role, into a comprehensive model of postmenopausal osteoporosis.
13 targets for various bone diseases, including postmenopausal osteoporosis.
14 he overall community prevalence of anemia or postmenopausal osteoporosis.
15 ans to control bone loss in diseases such as postmenopausal osteoporosis.
16 ly used for both prevention and treatment of postmenopausal osteoporosis.
17 py should be considered in the management of postmenopausal osteoporosis.
18 ans should follow guidelines established for postmenopausal osteoporosis.
19 of human age-related osteopenic diseases and postmenopausal osteoporosis.
20 en evaluated in the treatment of established postmenopausal osteoporosis.
21 d in the treatment of women with established postmenopausal osteoporosis.
22 aluation for the prevention and treatment of postmenopausal osteoporosis.
23 ting that alpha(v)beta3 blockade may prevent postmenopausal osteoporosis.
24 important implications for the treatment of postmenopausal osteoporosis.
25 aluation for the prevention and treatment of postmenopausal osteoporosis.
26 bone loss in the ovariectomy mouse model of postmenopausal osteoporosis.
27 bone protective effects in the treatment of postmenopausal osteoporosis.
28 ul and novel therapeutic approach to prevent postmenopausal osteoporosis.
29 ring the 5' end of PTHLH was associated with postmenopausal osteoporosis.
30 tment of osteoclast-related diseases such as postmenopausal osteoporosis.
33 es in reduced bone mass, similar to cases of postmenopausal osteoporosis and cancerous osteolysis.
34 sing therapeutic agent for the management of postmenopausal osteoporosis and rheumatoid arthritis.
35 and safety of denosumab for the treatment of postmenopausal osteoporosis and rheumatoid arthritis.
36 f therapeutic relevance for diseases such as postmenopausal osteoporosis and rheumatoid arthritis.
38 density, reduces fracture risk in women with postmenopausal osteoporosis, and inhibits structural dam
40 be effective for prevention and treatment of postmenopausal osteoporosis, but whether combination ant
41 and rs17013181, were associated with BMD and postmenopausal osteoporosis by the two-stage strategy, a
44 steoclast formation and resorption occurs in postmenopausal osteoporosis, inflammatory arthritis, and
46 onsible for the enhanced bone destruction in postmenopausal osteoporosis, Paget's disease, bone metas
48 nd plays a major role in the pathogenesis of postmenopausal osteoporosis, structural damage in rheuma
50 on bone mineral density (BMD) in women with postmenopausal osteoporosis transitioning from bisphosph
51 eview will focus on three new treatments for postmenopausal osteoporosis which have either been recen
52 olled women (aged >/=55 to </=90 years) with postmenopausal osteoporosis who had taken an oral bispho
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。